Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Aug. 15, 2022.
https://www.healio.com/news/ophthalmology/20220726/zimura-reduces-lesion-growth-in-geographic-atrophy
UBS Initiates Coverage IVERIC bio, Inc. (ISEE) $20.00 Buy
Usually companies announce 2-3 weeks in advance. Why the sudden announcement? Will there be something noteworthy happening beforehand?
It's up $32 dollars Extended Hours. --- * J The Legend !
$MEGL $AMTD $HKD $FAZE $SYM $KPLT $ISEE $DARE $ENVB $UWMC $ANY $DVAX $EXPR $KPTI $CHS $AIKI $AEI $APRN $EVGO $PHUN $HYLN $ MVIS $GOEV $MNMD $ROOT $MKD $BTBT $MMAT $NAK $AUPH $NNDM $SDC $GSAT $STEM $RDBX $IDEX $WE $DBGI $BNGO $BKKT $BB $OCGN $CLOV $ATER
$AEX $ARKK $AAL $AMC $AMD $AAPL $AMZN $APRN $ATER
$BBBY $BABA $BBI $BWV $BMEA $BBIG $BEAT $CCL $CEI
$ERIC $RIDE $SPCE $SKLZ $CSCW $FSR $GRAB $WISH $CLF $DIDI $FUBO $OPEN $BRQS $CYN $CEI $YLRY $FAMI $NOK $LCID $VALE $MULN $BBIG $SNDL $RIVN $CFVI $DWAC
$DAL $DKNG $GME $GLD $GLE $HOOD $HYMC $ITP $ING $IGEX
$JBLU $LCID $LUV $MULN $META $MULN $NCLH $NDX $PVSP
$QQQ $RCL $RDBX $SAVE $STRN $STEM $SPY $SAVE $SPX $SOFI $SNOA $TWTR $TKAT $TSLA $UAL $VERU $XRTX $XCUR $CENN $AEI $LYFT $JWN $DKS $WEN $INTU $NERO $WEJO $TTOO $VYNE $SIOX $ALNA $ROKU $ARKK $COMP $BHLB $ADER $OCGN $ALZN $ADTX $PLTR, $RKT $SOFI $SNDL $AGRX $DPLS $ADN $RIGL $QNRX $BOXD $EFOI $ASO, $SIGA $GFAI $REVB $FSRD $TOUR $CMRX, $CELZ, $FNHC $NBEV $COWN $RNW $OCFT $NISN $AAL $WISH $SOLO $APDN $BNGO $INO $VXRT $GCLT $CHNC $HIRU $VXIT $SSOF $GMPR $PASO $GMEV $SRMX $SANP $NNRX $FTEG $EEGI $CBDL $KYNC $WDLF $COWI $RMRK $FCGD $GWHP $GNBT $WLYYF $USEI $TGHI $NIOBF $BFCH $ZAAG $USMJ $JPEX $CZNI $MSPC $QNRX $LUNC.X $INPX $META $NVDA $MU $AMD $OXY $XOM $RIG $MRO $SWM $CVX $AMC $RBLX $DKNG $AAL $CCL $NCLH $CSX $PLTR $CLVS $MRNA$EVFM $LXRX $FCX $GOLD $KGC $HYMC $PGEN $GRAB $FFIE $DNA $NU $BLUE $UPS $KO $GM $MCD $GE $RTX $MMM $ADM $ACI $CNC $KMB $GLW $FISV $TRU $UBS $PHM $ECL $PII $ONB $CEQP $GPK $XRX $ARCC $IRDM $PCAR $MSCI $MCO $AAN $SSTK $FELE $PEBO $HUBB $WSO $AVNT $FFWM $PNR $ST $AWI $NXRT $CAC $CVLT
>> XELA << I'm In. --- * J The Legend !
$AMTD $HKD $FAZE $SYM $KPLT $ISEE $DARE $ENVB $UWMC $ANY $DVAX $EXPR $KPTI $CHS $AIKI $AEI $APRN $EVGO $PHUN $HYLN $ MVIS $GOEV $MNMD $ROOT $MKD $BTBT $MMAT $NAK $AUPH $NNDM $SDC $GSAT $STEM $RDBX $IDEX $WE $DBGI $BNGO $BKKT $BB $OCGN $CLOV $ATER
$AEX $ARKK $AAL $AMC $AMD $AAPL $AMZN $APRN $ATER
$BBBY $BABA $BBI $BWV $BMEA $BBIG $BEAT $CCL $CEI
$ERIC $RIDE $SPCE $SKLZ $CSCW $FSR $GRAB $WISH $CLF $DIDI $FUBO $OPEN $BRQS $CYN $CEI $YLRY $FAMI $NOK $LCID $VALE $MULN $BBIG $SNDL $RIVN $CFVI $DWAC
$DAL $DKNG $GME $GLD $GLE $HOOD $HYMC $ITP $ING $IGEX
$JBLU $LCID $LUV $MULN $META $MULN $NCLH $NDX $PVSP
$QQQ $RCL $RDBX $SAVE $STRN $STEM $SPY $SAVE $SPX $SOFI $SNOA $TWTR $TKAT $TSLA $UAL $VERU $XRTX $XCUR $CENN $AEI $LYFT $JWN $DKS $WEN $INTU $NERO $WEJO $TTOO $VYNE $SIOX $ALNA $ROKU $ARKK $COMP $BHLB $ADER $OCGN $ALZN $ADTX $PLTR, $RKT $SOFI $SNDL $AGRX $DPLS $ADN $RIGL $QNRX $BOXD $EFOI $ASO, $SIGA $GFAI $REVB $FSRD $TOUR $CMRX, $CELZ, $FNHC $NBEV $COWN $RNW $OCFT $NISN $AAL $WISH $SOLO $APDN $BNGO $INO $VXRT $GCLT $CHNC $HIRU $VXIT $SSOF $GMPR $PASO $GMEV $SRMX $SANP $NNRX $FTEG $EEGI $CBDL $KYNC $WDLF $COWI $RMRK $FCGD $GWHP $GNBT $WLYYF $USEI $TGHI $NIOBF $BFCH $ZAAG $USMJ $JPEX $CZNI $MSPC $QNRX $LUNC.X $INPX $META $NVDA $MU $AMD $OXY $XOM $RIG $MRO $SWM $CVX $AMC $RBLX $DKNG $AAL $CCL $NCLH $CSX $PLTR $CLVS $MRNA$EVFM $LXRX $FCX $GOLD $KGC $HYMC $PGEN $GRAB $FFIE $DNA $NU $BLUE $UPS $KO $GM $MCD $GE $RTX $MMM $ADM $ACI $CNC $KMB $GLW $FISV $TRU $UBS $PHM $ECL $PII $ONB $CEQP $GPK $XRX $ARCC $IRDM $PCAR $MSCI $MCO $AAN $SSTK $FELE $PEBO $HUBB $WSO $AVNT $FFWM $PNR $ST $AWI $NXRT $CAC $CVLT
$AMTD $HKD $FAZE $SYM $KPLT $ISEE $DARE $ENVB $UWMC $ANY $DVAX $EXPR $KPTI $CHS $AIKI $AEI $APRN $EVGO $PHUN $HYLN $ MVIS $GOEV $MNMD $ROOT $MKD $BTBT $MMAT $NAK $AUPH $NNDM $SDC $GSAT $STEM $RDBX $IDEX $WE $DBGI $BNGO $BKKT $BB $OCGN $CLOV $ATER
$AEX $ARKK $AAL $AMC $AMD $AAPL $AMZN $APRN $ATER
$BBBY $BABA $BBI $BWV $BMEA $BBIG $BEAT $CCL $CEI
$ERIC $RIDE $SPCE $SKLZ $CSCW $FSR $GRAB $WISH $CLF $DIDI $FUBO $OPEN $BRQS $CYN $CEI $YLRY $FAMI $NOK $LCID $VALE $MULN $BBIG $SNDL $RIVN $CFVI $DWAC
$DAL $DKNG $GME $GLD $GLE $HOOD $HYMC $ITP $ING $IGEX
$JBLU $LCID $LUV $MULN $META $MULN $NCLH $NDX $PVSP
$QQQ $RCL $RDBX $SAVE $STRN $STEM $SPY $SAVE $SPX $SOFI $SNOA $TWTR $TKAT $TSLA $UAL $VERU $XRTX $XCUR $CENN $AEI $LYFT $JWN $DKS $WEN $INTU $NERO $WEJO $TTOO $VYNE $SIOX $ALNA $ROKU $ARKK $COMP $BHLB $ADER $OCGN $ALZN $ADTX $PLTR, $RKT $SOFI $SNDL $AGRX $DPLS $ADN $RIGL $QNRX $BOXD $EFOI $ASO, $SIGA $GFAI $REVB $FSRD $TOUR $CMRX, $CELZ, $FNHC $NBEV $COWN $RNW $OCFT $NISN $AAL $WISH $SOLO $APDN $BNGO $INO $VXRT $GCLT $CHNC $HIRU $VXIT $SSOF $GMPR $PASO $GMEV $SRMX $SANP $NNRX $FTEG $EEGI $CBDL $KYNC $WDLF $COWI $RMRK $FCGD $GWHP $GNBT $WLYYF $USEI $TGHI $NIOBF $BFCH $ZAAG $USMJ $JPEX $CZNI $MSPC $QNRX $LUNC.X $INPX $META $NVDA $MU $AMD $OXY $XOM $RIG $MRO $SWM $CVX $AMC $RBLX $DKNG $AAL $CCL $NCLH $CSX $PLTR $CLVS $MRNA$EVFM $LXRX $FCX $GOLD $KGC $HYMC $PGEN $GRAB $FFIE $DNA $NU $BLUE $UPS $KO $GM $MCD $GE $RTX $MMM $ADM $ACI $CNC $KMB $GLW $FISV $TRU $UBS $PHM $ECL $PII $ONB $CEQP $GPK $XRX $ARCC $IRDM $PCAR $MSCI $MCO $AAN $SSTK $FELE $PEBO $HUBB $WSO $AVNT $FFWM $PNR $ST $AWI $NXRT $CAC $CVLT
Good Luck everyone.
Analysts polled by Capital IQ expected a loss of $0.32.
As expected, no revenue for the quarter ended June 30 was reported.
Operating expenses were $49.8 million in Q2, compared with $30.2 million a year earlier.
As of June 30, the company said it had $312 million in cash, cash equivalents and available-for-sale securities, compared with $381.7 million as of Dec. 31, 2021. The company said it expects to have between $260 million to $270 million by end of 2022.
Bank of America Securities Initiated IVERIC bio, Inc. (ISEE) $18.00 Buy
Guggenheim Initiated IVERIC bio, Inc. (ISEE) $30.00 Buy
“It has been a landmark year as we have achieved several major milestones for Zimura,” stated Glenn P. Sblendorio, Chief Executive Officer and President of IVERIC bio. “Over the past year, we announced positive 12-month and 18-month results from our GATHER1 Phase 3 clinical trial of Zimura for the treatment of geographic atrophy secondary to age-related macular degeneration. We initiated patient enrollment in GATHER2, our second Phase 3 clinical trial for the treatment of GA secondary to AMD. Additionally, we strengthened our balance sheet, advanced our two lead gene therapy product candidates to be on track to enter into the clinic next year and identified a lead compound for our HtrA1 inhibitor program.”
Pravin U. Dugel, M.D., Chief Strategy and Business Officer of IVERIC bio added, “We are excited about the momentum generated with Zimura as a potential treatment for GA and, based on scientific data, Zimura‘s potential impact in wet (neovascular) AMD and in earlier stages of dry AMD. We are also encouraged by our HtrA1 inhibitor, IC-500, which we believe could be another important target in the treatment of AMD. Looking forward, our goal is to expand our footprint in multiple stages and types of AMD, dry and wet. We intend to do this by potentially studying Zimura in additional indications and by advancing the development of IC-500. We expect to make great strides in 2021, as we continue to move our pipeline of therapeutics and gene therapy product candidates forward.”
Wedbush’s David Nierengarten initiated coverage of Iveric Bio with an Outperform rating and a price target of $13.
The Thesis
Geographic atrophy is estimated to represent a market opportunity of over $1 billion, with the current patient population at more than 1 million, Nierengarten said in the note.
In October, Iveric Bio had announced Zimura showed positive results in slowing the growth of lesions in its Phase 2 study. The company’s lead asset is also being investigated in Stargardt disease and data from this study could come as early as in the back half of 2002, the analyst noted.
Nierengarten expects more details of the trial design for Zimura’s pivotal study to be disclosed at Iveric Bio’s R&D investor symposium on Jan. 14.
He further wrote, “The company is also building a portfolio of gene therapy candidates, with the first program in autosomal dominant retinitis pigmentosa (adRP) likely to enter the clinic late this year.”
and the only ones left are the ones that bought those shares from the profit takers.
Where do you think the price will go now?
With a strong market this coming week for small caps and biotechs, we could do very well…….but what do I know?
😉